Ovarian Cancer

Novel Combination Shows Promise in Recurrent Ovarian Cancer

December 11th 2020, 6:45pm


A combination of pembrolizumab with bevacizumab and cyclophosphamide showed clinical activity and tolerability in patients with recurrent ovarian cancer, a small study found.

Top-line Phase 1 Results for Cantrixil Confirm Earlier Efficacy, Safety Signals

December 10th 2020, 1:43pm


Kazia Therapeutics will report the full results at a future scientific meeting.

Phase 1 Study of Novel Drug for Ovarian Cancer Shows Positive Results

December 5th 2020, 7:00pm


One patient had a complete response and the majority of patients achieved disease control at 12 weeks.

Assisted Reproductive Technology Does Not Increase Ovarian Cancer Risk

December 4th 2020, 10:00pm


New findings in Journal of the National Cancer Institute contradict previous research indicating that assisted reproductive technology might lead to an increased risk of ovarian cancer.

Study Examines Impact of Tumor Mutational Burden on Ovarian Cancer

November 25th 2020, 4:30pm


Tumor mutational burden is an emerging biomarker to predict response to immune checkpoint inhibitors, but its utility as a prognostic indicator in ovarian cancer is unclear.

Small Study Finds Potential Risk of Hematologic Abnormalities After Ovarian Cancer Treatment

November 24th 2020, 12:00pm


The new report suggests that patients treated with prolonged poly-ADP-ribose polymerase inhibitors after chemotherapy may need close hematological monitoring.

Patients With Ovarian Cancer Struggle With Uncertainty, Fears of Future, Study Finds

November 23rd 2020, 7:45pm


The dearth of effective treatment options for patients with ovarian cancer not only leads to poor health outcomes, but also leads to psychological distress, according to new research.

Review Offers First Head-to-Head Look at PARP Inhibitors for Ovarian Cancer

November 19th 2020, 6:00pm


Drawing on data from 6 randomized controlled trials accounting for over 2200 patients, the researchers the researchers compared the efficacy and safety of olaparib, rucaparib, and niraparib.

Careful Observation of Ovarian Cysts Safe Alternative to Surgery

February 9th 2019, 3:28am


Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.

Dr John Schorge Discusses Prevention Methods in Ovarian Cancer

June 30th 2018, 4:00pm


John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses different prevention methods in ovarian cancer.